Reirradiation on recurrent cervical cancer case: Treatment response and side effects

1st Physics and Technologies in Medicine and Dentistry Symposium

物理学;医药卫生

Siregar, M.F.^1 ; Supriana, N.^1 ; Nuranna, L.^2 ; Prihartono, J.^3

Department of Radiotherapy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia^1

Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia^2

Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia^3

关键词: Cancer recurrence;    Complete response;    General hospitals;    Late side effects;    Partial response;    Radiation treatments;    Treatment response;    Tumor progressions;   

Others  :  https://iopscience.iop.org/article/10.1088/1742-6596/884/1/012123/pdf
DOI  :  10.1088/1742-6596/884/1/012123

学科分类：卫生学

来源: IOP

【 摘 要 】

Management of recurrent cervical cancer by reirradiation after radiation treatment remains controversial. In Indonesia, there is currently no data about reirradiation tumor response and side effects. This study aims to assess the tumor response to and side effects of reirradiation, the effect of time interval between first radiation treatment and cancer recurrence on the tumor response and side effects, and the effect of tumor size on tumor response. A cohort retrospective study with no comparison was done with the Radiotherapy Department at Cipto Mangunkusumo General Hospital, Jakarta. Participants were recurrent cervical cancer patients undergoing reirradiation. Data was collected from patients' medical records and follow-up phone calls. Twenty-two patients participated in this study. Nine patients (40.9%) had complete responses, 10 patients (45.5%) had partial responses, 1 patient (4.5%) had a stable response, and 2 patients (9.1%) had tumor progressions. In general, 15 patients (68.2%) had no to light side effects (grade 0-2 RTOG) and 7 patients (31.8%) had severe side effects (grade 3-4 RTOG). Four patients (18.1%) had severe gastrointestinal acute side effects, 6 patients (27.3%) had severe gastrointestinal late side effects, 2 patients (9.1%) had severe urogenital side effects, and there were no patients had severe urogenital late side effects. There was no significant difference in tumor response between patients with time interval between first radiation treatment and recurrence of 4 cm. Reirradiation can be considered as a modality in recurrent cervical cancer management since good tumor response was achieved and the majority of patients had no to light side effects (grade 0-2 RTOG). This study found no correlation between tumor response, side effects, and time gap between first radiation treatment and recurrence of4 cm.